Mirum Pharmaceuticals Q2 2024 GAAP EPS $(0.52) Misses $(0.47) Estimate, Sales $77.875M Beat $75.246M Estimate
Mirum Pharmaceuticals Q2 2024 GAAP EPS $(0.52) Misses $(0.47) Estimate, Sales $77.875M Beat $75.246M Estimate
mirum pharmaceuticals 2024年第二季度的GAAP每股收益为$(0.52)，低于预计的$(0.47)，销售额为7787.5万美元，超过预计的7524.6万美元。
Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.64 percent. The company reported quarterly sales of $77.875 million which beat the analyst consensus estimate of $75.246 million by 3.49 percent. This is a 107.68 percent increase over sales of $37.497 million the same period last year.
Mirum Pharmaceuticals (纳斯达克股票代码：MIRM)报告本季每股亏损为$(0.52), 较分析师共识预期$(0.47)低10.64%。该公司本季度销售额为$77.87500百万，超出分析师预期的$75.24600百万，增长3.49%。这增长了107.68%，去年同期销售额为$37.49700百万。